1-methyl-2-[(2-aminophenoxy)methyl]1H-imidazole | 267431-25-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-methyl-2-[(2-aminophenoxy)methyl]1H-imidazole
• 英文别名: 1-methyl-2-[(2-aminophenoxy)methyl]-1H-imidazole；2-[(1-methylimidazol-2-yl)methoxy]aniline
• CAS: 267431-25-4
• 化学式: C₁₁H₁₃N₃O
• 分子量: 203.244
• InChiKey: NZQZUEYNAHQNLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  53.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-methyl-2-[(2-nitrophenoxy)methyl]-1H-imidazole 在 钯 silica gel 、 chloroform methanol 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、45.96 MPa 条件下， 反应 6.0h， 以giving rise 0.856 g of the title compound as a red oil的产率得到1-methyl-2-[(2-aminophenoxy)methyl]1H-imidazole
  参考文献：
  名称：

  2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents

  摘要：

  化合物是公式（I）的2-脲基-1,3-噻唑衍生物，其中R是卤素原子，硝基，可选择性取代的氨基或者是一种基团，可选择性进一步取代，选择自：i）直链或支链C1-C6烷基；ii）C3-C6环烷基；iii）在直链或支链烷基链中含有1至6个碳原子的芳基或芳基烷基；R1是可选择性取代的基团，选择自：i）直链或支链C1-C6烷基；ii）3至6个成员的碳环或5至7个成员的杂环环；iii）芳基或芳基羰基；iv）在直链或支链烷基链中含有1至6个碳原子的芳基烷基：R2是氢，直链或支链C1-C4烷基或C2-C4烯基或炔基；或者，与它们所结合的氮原子一起，R1和R2形成一个取代或未取代的基团，选择自：i）可选择性苯并或桥接的5至7个成员的杂环；或ii）一个9至11个成员的螺-杂环化合物；或其药学上可接受的盐；对于治疗与改变的细胞依赖性激酶活性相关的细胞增殖性疾病有用。

  公开号：

  US20030187040A1

文献信息

• 2-UREIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS
  申请人：PHARMACIA & UPJOHN S.p.A.

  公开号：EP1124811A1

  公开（公告）日：2001-08-22
• US6863647B2
  申请人：——

  公开号：US6863647B2

  公开（公告）日：2005-03-08
• [EN] 2-UREIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS<br/>[FR] DERIVES DE 2-UREIDOTHIAZOLS, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION COMME AGENTS ANTITUMORAUX
  申请人：PHARMACIA & UPJOHN SPA

  公开号：WO2000026203A1

  公开（公告）日：2000-05-11

  Compounds which are 2-ureido-1, 3-thiazole derivatives of formula (I) wherein R is a halogen atom, a nitro group, an optionally substituted amino group or it is a group, optionally further substituted, selected from: i) straight or branched C1-C6 alkyl; ii) C3-C6 cycloalkyl; iii) aryl or arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain; R1 is an optionally substituted group selected from: i) straight or branched C1-C6 alkyl; ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring; iii) aryl or arylcarbonyl; iv) arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain; R2 is hydrogen, a straight or branched C1-C4 alkyl or C2-C4 alkenyl or alkynyl group; or, taken together with the nitrogen atom to which they are bonded, R1 and R2 form a substituted or unsubstituted group selected from: i) an optionally benzocondensed or bridged 5 to 7 membered heterocycle; or ii) a 9 to 11 membered spiro-heterocyclic compound; or a pharmaceutically acceptable salt thereof; are useful for treating cell proliferative disorders associated with an altered cell dependent kinase activity.